If short sellers were hoping for a flop from Hims & Hers Health Inc. (NYSE:HIMS), they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after the bell on Monday, and instead of the crash shorts were counting on, the market got a bullish cocktail: strong guidance, solid revenue growth and a headline-making partnership with Novo Nordisk A/S (NYSE:NVO).

Shares popped – and they’ve kept climbing.

Read Also: Hims & Hers Stock Soars 32% Since Tuesday On Strong Q1 Earnings And Robust Outlook

HIMS Stock Up 100% In A Month

HIMS is now up 100% in the past month and more than 100% year-to-date, defying bears who bet on a post-compounding hangover after the FDA signaled the end of semaglutide shortages.

Short interest remains stubbornly high – about 33% of the float, per NYSE data. That's a significant chunk of the stock sitting in borrowed hands, and every uptick tightens the squeeze.

Chart created using Benzinga Pro

The technicals are no help to the pessimists. HIMS trades at $51.12, well above its eight-day, 20-day, 50-day, and even 200-day moving averages—a strong bullish trend by any measure.

This might already be the start of a classic short squeeze: earnings didn't break the bull run, and instead of pulling back, the stock gained even more traction. That means shorts sitting on losses are either holding out for a miracle or quietly covering before things get worse.

The bears may have been early – but if this trend holds, they're about to be steamrolled. Hims & Hers isn't just selling weight-loss meds anymore… it might be handing out humble pie.

Read Next:

• Top 3 Health Care Stocks That Could Sink Your Portfolio In Q2

Photo: Shutterstock